Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Videos

BDHC thumbnail
Breaking Down Health Care
The Balance Between Drug Safety and Availability
06/17/2024
Michael Kolodziej, MD
John Hennessy, MBA
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the process of drug approvals and the role of the US Food and Drug Administration, including how and why the process takes so much time—and...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the process of drug approvals and the role of the US Food and Drug Administration, including how and why the process takes so much time—and...
In this Breaking Down Health...
06/17/2024
Cancer Care Business Exchange
William J. Gradishar, MD
Videos
HR-Positive and HER2-Negative Breast Cancer Treatment Updates
06/04/2024
William J. Gradishar, MD
William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer.
William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer.
William J. Gradishar, MD,...
06/04/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
Medicare for All: Careful What You Wish for
06/03/2024
Michael Kolodziej, MD
John Hennessy, MBA
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of Medicare for All and universal health care: why these terms are not interchangeable, and if they could actually solve the...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of Medicare for All and universal health care: why these terms are not interchangeable, and if they could actually solve the...
In this Breaking Down Health...
06/03/2024
Cancer Care Business Exchange
Natasha Leighl, MD
Conference Coverage
Subcutaneous vs Intravenous Amivantamab Plus Lazertinib for Patients With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
06/01/2024
Natasha Leighl, MD
Natasha Leighl, MD, discussed results from the phase 3 PALOMA-3 trial which compared subcutaneous and intravenous amivantamab plus lazertinib in patients with advanced, EGFR-mutated non-small cell lung cancer.
Natasha Leighl, MD, discussed results from the phase 3 PALOMA-3 trial which compared subcutaneous and intravenous amivantamab plus lazertinib in patients with advanced, EGFR-mutated non-small cell lung cancer.
Natasha Leighl, MD, discussed...
06/01/2024
Oncology
Videos
It Takes a Village: Managing the Needs of All Stakeholders in Value-Based Care Models
05/31/2024

Barry Russo, MBA, the Center for Cancer and Blood Disorders

Barry Russo, MBA, the Center for Canc...
Barry Russo, MBA, breaks down how collaboration between stakeholders leads to more comprehensive care in value-based care models.
Barry Russo, MBA, breaks down how collaboration between stakeholders leads to more comprehensive care in value-based care models.
Barry Russo, MBA, breaks down...
05/31/2024
Journal of Clinical Pathways
Sarah Smith, Virginia Cancer Specialists
Videos
Post-Progression and Safety Outcomes With First-Line Amivantamab Plus Lazertinib vs Osimertinib for Advanced NSCLC: Best Management Practices
05/24/2024
Sarah Smith, BD, CNMT, discusses findings from the phase 3 MARIPOSA study exploring post-progression and safety outcomes with first-line amivantamab plus lazertinib vs osimertinib for advanced NSCLC and offers guidance for best management...
Sarah Smith, BD, CNMT, discusses findings from the phase 3 MARIPOSA study exploring post-progression and safety outcomes with first-line amivantamab plus lazertinib vs osimertinib for advanced NSCLC and offers guidance for best management...
Sarah Smith, BD, CNMT, discusses...
05/24/2024
Oncology
BDHC thumbnail
Breaking Down Health Care
The Bear: Why Does Health Care Cost So Much? (Part 2)
05/20/2024
Michael Kolodziej, MD
John Hennessy, MBA
In part two of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into the other main stakeholders in health care costs: pharmaceutical manufacturers and providers. They discuss how these...
In part two of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into the other main stakeholders in health care costs: pharmaceutical manufacturers and providers. They discuss how these...
In part two of this two-part...
05/20/2024
Cancer Care Business Exchange
Lalan Wilfong, MD
Videos
Balancing the Benefits and Risks of Value-Based Care Arrangements
05/16/2024
Lalan Wilfong, MD
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his...
05/16/2024
Journal of Clinical Pathways
Edward Garon, MD, MS
Conference Coverage
Should Docetaxel Plus Ramucirumab Be the Standard Second-Line Option for Patients With Non-Small Cell Lung Cancer?
05/15/2024
Edward Garon, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.
At the Great Debates and Updates...
05/15/2024
Oncology
BDHC thumbnail
Breaking Down Health Care
The Bear: Why Does Health Care Cost So Much? (Part 1)
05/06/2024

Featuring Michael Kolodziej, MD, and John Hennessy, MBA

Featuring Michael Kolodziej, MD, and ...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part...
05/06/2024
Cancer Care Business Exchange
JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Popular Articles

Sarena Ho, MSPH
Quality Outlook
Quality Measures for Medicare’s Enhancing Oncology Model (EOM): New and Improved or More of the Same?
01/26/2023

David Blaisdell; Sarena Ho, MSPH; Tom Valuck, MD, JD

David Blaisdell; Sarena Ho, MSPH; Tom...
This blog discusses the Center for Medicare & Medicaid Service’s efforts to advance cancer quality through its new Enhancing Oncology Model (EOM) and presents recommendations for strengthening the EOM measure set and aligning measures across...
This blog discusses the Center for Medicare & Medicaid Service’s efforts to advance cancer quality through its new Enhancing Oncology Model (EOM) and presents recommendations for strengthening the EOM measure set and aligning measures across...
This blog discusses the Center...
01/26/2023
Journal of Clinical Pathways
Developing Pathway to Cure: A Multimodal Clinical Pathway Platform to Support Timely and Appropriate Care of Women Under 50 Diagnosed With Breast Cancer
From the Field
Developing Pathway to Cure: A Multimodal Clinical Pathway Platform to Support Timely and Appropriate Care of Women Under 50 Diagnosed With Breast Cancer
09/18/2020
Robin M Lally, PhD, MS, RN, AOCN, FAAN1,2
Roksana Zak, PhD1
Ryan Ramaekers, MD3
Allison F Coates, BS, BSN, RN1
Elizabeth Reed, MD2
Abstract: Pathway to Cure is a multimodal eHealth platform for oncology care providers and patients developed by a multidisciplinary team at the University of Nebraska Medical Center’s Fred & Pamela Buffett...
Abstract: Pathway to Cure is a multimodal eHealth platform for oncology care providers and patients developed by a multidisciplinary team at the University of Nebraska Medical Center’s Fred & Pamela Buffett...
...
09/18/2020
Journal of Clinical Pathways
Transformative Employer Trends
Employer Commercial Insurance Landscape
06/05/2023
F. Randy Vogenberg, PhD, FASHP
This first installment of the new “Transformative Employer Trends” column explores the employer’s perspective when it comes to utilizing and developing pathways of care, including how they manage risk, their care plans and strategies, and...
This first installment of the new “Transformative Employer Trends” column explores the employer’s perspective when it comes to utilizing and developing pathways of care, including how they manage risk, their care plans and strategies, and...
This first installment of the...
06/05/2023
Journal of Clinical Pathways
The Role and Scope of Practice of Advanced Practice Providers in United States Community Oncology
Research Reports
The Role and Scope of Practice of Advanced Practice Providers in United States Community Oncology
04/21/2020
Ajeet Gajra, MD, FACP1
Chadi Nabhan, MD, MBA2
Andrew J Klink, PhD, MPH1
Ting-Chun Yeh, PhD1
Bela Bapat, MS3
Yolaine J Smith, PhD1
Bruce A Feinberg, DO1
Abstract: In the era of value-based care and constrained resources, oncology practices are increasingly employing advanced practice providers (APPs) to improve practice workflow, increase efficiency, and enable...
Abstract: In the era of value-based care and constrained resources, oncology practices are increasingly employing advanced practice providers (APPs) to improve practice workflow, increase efficiency, and enable...
...
04/21/2020
Journal of Clinical Pathways

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement